#esmo abstracts

[mariebenz]

Larotrectinib (VITRAKVI® ): Efficacy and Safety in Pediatric TRK Fusion Cancer Patients

MedicalResearch.com Interview with

Dr. Hawkins Douglas S. Hawkins, M.D. Hematology/Oncology Division Chief and Professor Pediatrics at Seattle Children's Hospital University of Washington School of Medicine MedicalResearch.com: What is the background for this study? Response: TRK fusion cancer is caused by a rare genomic alteration called a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Larotrectinib is a central nervous system (CNS) active, oral and highly selective TRK inhibitor used for the treatment of adult and pediatric patients with solid tumors that have a rare genomic alteration called an NTRK gene fusion. Larotrectinib was approved at the end of 2018 in the U.S. under the brand name VITRAKVI®, with European and worldwide regulatory submissions underway. At ASCO 2019, we will be presenting results from a new analysis specifically looking at the efficacy and safety of larotrectinib in pediatric patients (n=34) included in the expanded dataset from both adults and children across 24 tumor types, which was presented first at the European Society for Medical Oncology (ESMO) 2019 Annual Meeting.  MedicalResearch.com: What are the main findings? Response: In children with TRK fusion cancer, the analysis found an overall response rate (ORR) of 94 percent, with 12 patients achieving complete responses, 18 patients achieving partial responses (PR), and two patients with PRs pending confirmation. At the time of data cut-off of July 30, 2018, the median duration of response had not been reached (range 1.6+ to 26.7+ months), with 84 percent of patients on treatment for greater than one year. The analysis further found that safety data were consistent with previous publications, with the majority of adverse events being grade 1 or 2. MedicalResearch.com: What should readers take away from your report? Response: The data presented from this analysis reinforce the efficacy of larotrectinib in children with TRK fusion cancer. The high and durable response rates further confirm the consistent efficacy and safety of larotrectinib in patients with TRK fusion cancer regardless of tumor type and age. Larotrectinib represents a meaningful advancement in the fight against cancer, as it treats the oncogenic driver that causes tumor spread and growth, rather than where the tumor originates in the body.  MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: The efficacy observed in the new analysis with the use of larotrectinib warrants broader adoption of high-quality testing for cancer patients to detect NTRK gene fusions along with other potential targets. Testing for TRK fusion cancer as part of comprehensive tumor profiling will allow researchers to transform the epidemiological profile by identifying patients that are most likely to benefit from larotrectinib.  Disclosures: Dr. Hawkins received reimbursement for travel to attending Medical Advisory Board Meetings for Bayer and Loxo Oncology.  He has been a speaker at a Bayer Product Theater discussing larotrectinib.  He has not received honoraria or other compensation as a Medical Advisory Board member or as a speaker.  Seattle Children’s Hospital received research funding from Bayer and Loxo Oncology to cover the cost of the conduct of clinical trials conducted at the institution, for which Dr. Hawkins was an investigator. Citation: ASCO 2019 Abstract #10010: Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.   The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

#bayerpharma #pediatriccancer #PediatricPulse #pediatrics #UW #VITRAKVI®

[cancersfakianakis1]

A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: accurate review of management and perspectives

Publication date: Available online 13 October 2018

Source: Critical Reviews in Oncology/Hematology

Author(s): Antonio Chiappa, Bruno Andreoni, Renzo Dionigi, Lorenzo Spaggiari, Diego Foschi, Gianluca Polvani, Roberto Orecchia, Nicola Fazio, Gabriella Pravettoni, Maria Laura Cossu, Domenico Galetta, Marco Venturino, Carlo Ferrari, Lorenzo Macone, Cristiano Crosta, Bernardo Bonanni, Roberto Biffi

Abstract

Cancer of the esophagus and of gastroesophageal junction can be cured, even if with lacking cure rate. Different approaches have been developed, mostly when carcinoma has loco-regional pattern. Multimodality therapy showed a survival rate superior than 10% if compared to a single approach. This is a systematic review, carried to assess the following matters: Which therapeutic opportunities are available? Who could benefit of them? Which adverse reactions could possibly verify? How can physicians definitely choose the proper strategy? Which is the role of surgery? We mean to give either General Practitioner or specialists clear and efficient updates about current treatment of this tumour, starting from physical examination. Four eminent guidelines were consulted for our study: Cancer Care Ontario’s Program in Evidence-Based Care, NCCN, Belgian Health Care Knowledge Centre and Esmo.

Graphical abstract

https://ift.tt/2A8xBkQ

#Oncology-Sfakianakis

[allineednow]

<p>Osimertinib Enhances progression-free survival in Asian EGFR-mutated lung cancer patients</p>

LUGANO, 20 November 2017 - Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress (1), sumultaneously printed in The New England Journal of Medicine. (2)

Mutations occur in 30-40 percent of NSCLC in populations compared to 10-15 percent in Western populations. The stage III FLAURA trial compared osimertinib, a third generation EGFR-tyrosine kinase inhibitor (TKI), to standard of care EGFR-TKIs (erlotinib or gefitinib) as first line therapy in NSCLC patients with EGFR mutations. A total of 556 patients from North America, Europe, and Asia have been randomised 1:1 with osimertinib or standard of care to remedy. Osimertinib enhanced progression-free survival by 54%.

This subset analysis included the Asian patients in the FLAURA trial, of 120 were Japanese, and 156 were from other parts of Asia.

The median progression-free survival was 16.5 months with osimertinib compared to 11.0 weeks for the standard therapy, with a hazard ratio of 0.54 (95% confidence interval, 0.41-0.72; p

The median duration of response was two-fold greater for patients treated with osimertinib (17.6 months) compared to standard of care (8.7 months). The response rate was 80% with osimertinib compared to 75% with standard of care treatment. Median survival wasn't reached. The incidence of grade 3 or greater toxicities was lower for osimertinib (40%) than the conventional treatment (48%).

Lead author Professor Byoung Chul Cho, Yonsei Cancer Center, Seoul, Korea, said: "As in the general trial population, osimertinib supplied a significant progression-free survival benefit in Asian patients with EGFR-mutated NSCLC. Patients had similar toxicities with osimertinib. Osimertinib are the preferred first line treatment for EGFR-mutant NSCLC in Asia."

Commenting on the findings Professor James CH Yang, Chairman, Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei City, Taiwan, said: "The results of this subset analysis are very compatible with the findings in the overall population presented in the ESMO 2017 Congress at Madrid. (3) We can therefore conclude that osimertinib could be regarded as the standard of care for the first line treatment of Asian advanced NSCLC patients with EGFR mutations."

"The proportion of patients with adverse events that caused them to quit taking osimertinib was similar in the overall (13%) and Asian (15 percent) populations," added Yang. "We tend to think osimertinib is a well tolerated drug so these discontinuation rates were surprisingly high and need further investigation."

Yang continued: "Although there was no statistical difference between the hazard ratios for progression-free survival, it was numerically lower in non-Asians (0.34) compared to Asians (0.54). There is an ongoing debate as to whether Asian and non-Asian patients with mutations have different responses. This might be due to variations in practice rather than biology. A meta-analysis of all relevant studies could shed light on this issue."

"It will also be important to understand whether Asian and non-Asian patients at the FLAURA trial with brain metastases had similar outcomes," said Yang. (4)

###

Notes to Editors

Please make sure to use the official name of the meeting in your accounts: ESMO Asia 2017 Congress

References

(1) Abstract LBA6_PR 'Osimertinib versus standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset' will be shown by Byoung Chul Cho through the Mini Oral session Thoracic malignancies 2 on Sunday, 19 November 2017, 14:30 to 15:25 (SGT) in Room 310. Annals of Oncology, Volume 28, 2017 Supplement 10

(2) 'Osimertinib at treatment-naïve EGFR mutation-positive advanced NSCLC (FLAURA)' S Ramalingam et al, The New England Journal of Medicine (NEJM), 10.1056/NEJMoa1713137, NEJMoa1713137

(3) Abstract LBA2_PR 'Osimertinib vs SoC EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA)' S. Ramalingam et al.. Annals of Oncology, Volume 28, 2017 Supplement 5

(4) Abstract LBA5 'CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the FLAURA research' will be presented by Johan Vansteenkiste through the Proffered paper session 1 on Saturday, 18 November 2017, 08:30 to 10:30 (SGT) at Hall 405. Annals of Oncology, Volume 28, 2017 Supplement 10

Disclaimer

This press release includes information supplied by the authors of the highlighted abstracts and reflects the content of these abstracts. It does not necessarily reflect opinions or the views of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology (ESMO)

ESMO is the expert organisation for oncology. With 17,000 members representing professionals from 150 countries globally, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and progress in a environment. org

Twitter: @myESMO; #ESMOAsia17

Facebook:

Youtube:

[was-ist-los-in-oesterreich]

#Wirtschaft

[tumimmtxpapers]

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer.

Related Articles Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open. 2019;4(3):e000523 Authors: Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA Abstract Background: Accumulating evidence suggests immunomodulatory and context-dependent effects of TP53 mutations in cancer. We performed an exploratory analysis of the transcriptional, immunobiological and prognostic associations of TP53 mutations within the gene expression-based consensus molecular subtypes (CMSs) of colorectal cancer (CRC). Materials and methods: In a single-hospital series of 401 stage I-IV primary CRCs, we sequenced the whole coding region of TP53 and analysed CMS-dependent transcriptional consequences of the mutations by gene expression profiling. Immunomodulatory associations were validated by multiplex, fluorescence-based immunohistochemistry of immune cell markers. Prognostic associations of TP53 mutations were analysed in an aggregated series of 635 patients classified according to CMS, including publicly available data from a French multicentre cohort (GSE39582). Results: TP53 mutations were found in 60% of the CRCs. However, gene set enrichment analyses indicated that their transcriptional consequences varied among the CMSs and were most pronounced in CMS1-immune and CMS4-mesenchymal. Subtype specificity was primarily seen as an upregulation of gene sets reflecting cell cycle progression in CMS4 and a downregulation of T cell activity in CMS1. The subtype-dependent immunomodulatory associations were reinforced by significant depletion of several immune cell populations in mutated tumours compared with wild-type (wt) tumours exclusively in CMS1, including cytotoxic lymphocytes (adjusted p value in CMS1=0.002 and CMS2-4>0.9, Microenvironment Cell Populations (MCP)-counter algorithm). This was validated by immunohistochemistry-based quantification of tumour infiltrating CD8+ cells. Within CMS1, the immunomodulatory association of TP53 mutations was strongest among microsatellite stable (MSS) tumours, and this translated into a propensity for metastatic disease and poor prognostic value of the mutations specifically in the CMS1/MSS subtype (both series overall survival: TP53 mutation vs wt: HR 5.52, p=0.028). Conclusions: Integration of TP53 mutation status with the CMS framework in primary CRC suggested subtype-dependent immunobiological associations with prognostic and potentially immunotherapeutic implications, warranting independent validation. PMID: 31321083 [PubMed] http://dlvr.it/R8mMZY

[bharatiyamedia-blog]

Higher consciousness wanted of abdomen most cancers threat in under-40s, particularly in Latin America

http://tinyurl.com/yy8rjl67 IMAGE: Summary – P-145 ‘Gastric most cancers in younger Latin girls: unhealthy prognostic elements and outcomes’ shall be introduced by Germán Calderillo-Ruiz in the course of the Poster Session on Four July, 11:10-11:30 CEST…. view more  Credit score: @European Society for Medical Oncology Barcelona, Spain, 2 July 2019 – Abdomen most cancers ought to now not be thought of a illness solely of older individuals, and sufferers underneath 40 with persistent digestive signs ought to be extra actively investigated – particularly if they’re of Latin American ethnicity. This recommendation follows new knowledge from a retrospective, observational examine in Mexico which confirmed that one in seven of over 2,000 sufferers recognized with gastric most cancers between 2004 and 2016 had been underneath 40. These findings, reported on the ESMO World Congress on Gastrointestinal Most cancers 2019, (1,2) assist US Nationwide Most cancers Institute knowledge exhibiting that gastric most cancers is affecting extra younger Hispanic individuals, with worse outcomes than in older sufferers. “At our centre, we’ve seen a 120% enhance in gastric most cancers in youthful sufferers within the final 12 years and this enhance has been primarily in feminine sufferers who usually current with extra superior illness and worse prognostic indicators than males, with an antagonistic impression on survival,” stated examine creator Dr German Calderillo-Ruiz, from the Nationwide Most cancers Institute, Tlalpan, Mexico. Within the Mexican examine, over half of sufferers underneath 40 with gastric most cancers had been girls, in distinction to earlier analysis which has usually proven that gastric most cancers is most typical in males. Feminine sufferers in Mexico had been extra more likely to have diffuse-type and poorly differentiated tumours and later stage illness at prognosis than male sufferers, with a considerably decrease general survival. “The shortage of monetary sources could impression on girls’s behaviour of delaying pursuit of medical care when gastric signs seem. We hope this analysis will encourage clinicians and sufferers to be extra conscious of the chance of gastric most cancers in youthful individuals and, specifically, to encourage girls with gastric signs to hunt medical assist sooner,” stated Calderillo-Ruiz. Commenting on the implications of the analysis, Dr Rodrigo Dienstmann, from Vall d’Hebron Institute of Oncology, Barcelona, Spain, highlighted the mix of genetic and environmental elements that contribute to gastric most cancers and the truth that younger individuals with gastric most cancers have extra aggressive illness which is much less aware of healing therapy. “We can’t change the genetic elements however we are able to act on the unhealthy food plan, weight problems, and untreated Helicobacter pylori an infection which enhance the chance of gastric most cancers. Helicobacter an infection may cause persistent irritation and lesions which can be precursors to gastric most cancers however, as soon as recognized, could be cured with a mixture of antibiotics and medicines to scale back abdomen acid,” stated Dienstmann. “Youthful individuals who repeatedly expertise indigestion, heartburn or different gastric signs mustn’t ignore them however ought to go to their physician as they in all probability want diagnostic assessments. As well as, clinicians mustn’t ignore the potential of gastric most cancers in younger inhabitants, notably in Latin America or amongst Hispanics in North America.” concluded Dienstmann. Following the newest analysis in Mexico, epidemiological and molecular research are being carried out in Latin America and Europe to analyze the totally different molecular subtypes of gastric most cancers within the areas and enhance our understanding of threat elements in these populations. (3) Examine outcomes Within the Mexican examine, knowledge from 2,022 sufferers with gastric adenocarcinoma recognized between 2004 and 2016 had been analysed, of whom 290 sufferers (14%) had been underneath 40. Of those, 54% had been girls and 46% had been males. Girls had increased ranges of things indicating poor prognosis than males: diffuse-type tumour (68% vs 32%; P=0.127), ring-seal cells (76% vs 69%; P=0.049), poorly-differentiated (89% vs 84%; P=0.014) and better prevalence of stage IV illness (59% vs 41%; P=0.011). Total survival was a median of seven versus Eight months for ladies and men respectively (P=0.03; hazard ratio (HR) 1.29; 95% CI, 1.05-1.65). Median general survival was considerably worse in sufferers with tumours on the oesophagogastric junction: 7 vs 14 months (P=0.23; HR 0.68; 95% CI, 1.05-2.688) and extra superior illness: clinical-stages I-III, domestically superior and stage IV 33, 12, and 5 months, respectively (P=0.001; HR=2.28; 95% CI, 1.72-3.01). Unbiased predictors of general survival had been maintained in a Cox-Regression evaluation: gender (P=0.038, HR 1.29, 95% CI 1.01-1.65), major tumor (P=0.02, HR 1.68, 95% CI 1.05-2.68) and clinical-stage (P=0.001, HR 2.28, 95% CI 1.72-3.01). ### Notes to Editors Please make sure that to make use of the official title of the assembly in your stories: ESMO World Congress on Gastrointestinal Most cancers 2019 Official Congress Hashtag: #WorldGI2019 Disclaimer This press launch comprises data offered by the creator of the highlighted summary and displays the content material of these abstracts. It doesn’t essentially replicate the views or opinions of ESMO who can’t be held liable for the accuracy of the information. Commentators quoted within the press launch are required to adjust to the ESMO Declaration of Pursuits coverage and the ESMO Code of Conduct. References 1 https://www.esmo.org/Conferences/ESMO-World-GI-2019 2 Summary – P-145 ‘Gastric most cancers in younger Latin girls: unhealthy prognostic elements and outcomes’ shall be introduced by German Calderillo-Ruiz in the course of the Poster Session on Four July, 11:10-11:30 CEST. Annals of Oncology 30 (Complement 4): iv137-iv151, 2019 Three Tasks such because the Legacy mission financed by European Fee Horizon 2020 grants (https://legacy-h2020.eu/) In regards to the ESMO World Congress on Gastrointestinal Most cancers The ESMO World Congress on Gastrointestinal Most cancers represents the yr’s most essential gathering designed to concentrate on reversing the present world statistics that rank gastrointestinal malignancies because the main causes of most cancers deaths worldwide. Summary P-145 – Gastric most cancers in younger Latin girls: unhealthy prognostic elements and outcomes G Calderillo-Ruiz1, A Takahashi2, M Herrera3, A Padilla4, E Trejo3, M Ramos-Ramirez5, B Carbajal3, A Albarran3 1National Most cancers Institute, Tlalpan , Mexico, 2National Most cancers Institute, Mexico, Mexico, 3National Most cancers Institute, Tlalpan, Mexico, 4National Most cancers Institute, Tlalpan, Mexico, 5National Most cancers Institute, Mexico Metropolis, Mexico Introduction: Gastric most cancers (GC) has been thought of a illness of the older inhabitants worldwide. Within the final decade, GC has elevated within the youthful inhabitants (lower than or equal to 40 years) as much as 15%, with a better incidence in girls. These sufferers stay asymptomatic with late prognosis and poor prognostic elements reminiscent of kind and histological grade. The purpose of this examine was to explain the prevalence and prognostic elements, and their relationships with general survival (OS) in Latin sufferers with gastric adenocarcinoma lower than or equal to 40 years handled at INCAN, Mexico. Strategies: This was a retrospective, observational examine, from 2004 to 2016. Measures of central tendency, Kaplan-Meier, log-rank, and Cox regression mannequin had been used for the calculation of OS and issue evaluation between the teams with P Outcomes: We analyzed 2022 sufferers with gastric adenocarcinoma, of whom 14% (n=290) had been sufferers lower than or equal to 40 years. Of those, 54% had been girls and 46% had been males, with a imply age of 34.6 years (CI 4,9) in each teams. A 120% enhance in younger sufferers with GC has been documented within the final 12 years. The places of the first tumors had been gastric (93%) and the esophagogastric junction (UEG) (7%). Histological knowledge had been as follows: diffuse-type (70%), cells-ring-seal (72%), and poor-differentiated (87%). They had been categorised as the next: Medical-stage I-III (8%) by whole or partial gastrectomy; domestically superior (LA) (16%); and Medical-stage IV (76%) by tomography and/or laparoscopy. All sufferers acquired the standard oncological therapy+/-support therapy authorised by the institutional administration pointers. Comparatively, girls confirmed increased poor prognostic elements: diffuse-type (68%; P=0.127), ring-seal cells (76%; P=0 .049), poor-differentiated (89%; P=0 .014) and better prevalence of EC-IV (59%; P=0 .011) in comparison with 32%, 69%, 84%, and 41% for males respectively. In OS evaluation, a median of seven versus Eight months was noticed for ladies and men (P=0.030;HR 1.29; 95% CI, 1.05-1.65). Concerning major tumor, median-OS for gastric tumors was 7 months versus 14 months for UEG (P=0.23; HR 0.68; 95% CI, 1.05-2.688). As well as, important variations had been noticed in median-OS between Medical-Phases I-III, LA and IV with 33, 12, and 5 months, respectively (P=0 .001; HR1/42.28; 95% CI, 1.72- 3.01). Within the Cox-Regression evaluation, unbiased predictors of OS had been maintained in Gender (p=0.038, HR 1.29, 95% CI 1.01-1.65) , Major tumor (p=0.020, HR 1.68, 95% CI 1.05-2.68) and Medical-stage (p=0.001, HR 2.28, 95% CI 1.72-3.01), diffuse-type, ring-seal-cells and little-differentiation present no statistical significance. Conclusion: The incidence of GC within the youthful inhabitants has been growing over the past 12 years, with a higher incidence in females, opposite to what’s seen in sufferers over 40 years. Poor prognosis elements reminiscent of clinical-stage IV, diffuse-type adenocarcinoma, presence of ring-seal cells, and poor-differentiation are extra frequent in younger girls, exhibiting a lower in OS. Source link

[disturbingnuisance]

Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age

Presented at: 2020 ESMO World Congress on Gastrointestinal Cancer Virtual Meeting; July 1-4, 2020; Virtual. Abstract S-O3. Results from an additional ... from Google Alert - gastrointestinal https://ift.tt/2ApwvnF

#IFTTT #Google Alert - gastrointestinal

[jcnnewswire]

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020

http://dlvr.it/RgNgYF

[neurocirurgiabr]

How we treat patients with leptomeningeal metastases.

ESMO Open. 2019 May 21;4(Suppl 2):e000507. doi: 10.1136/esmoopen-2019-000507. eCollection 2019. How we treat patients with leptomeningeal metastases. Le Rhun E1,2, Preusser M3, van den Bent M4, Andratschke N5, Weller M2. Author information Abstract

The goal of treatment of leptomeningeal metastasis is to improve survival and to maintain quality of life by delaying neurological deterioration.…

View On WordPress

#aneurisma cerebral #CANCER #cirurgia da coluna #consulta neurocirurgião #consultório neurocirurgião #dor de cabeça #estudante de medicina #faculdade de medicina #julio pereira #julio pereira neurocirurgião #medicina #melhor neurocirurgia #melhor neurocirurgião #melhor neurocirurgião brasil #melhor neurocirurgião sp #METASTASE #microsurgery #Neurocirurgia #neurocirurgiabr #neurocirurgião sp #neurointensivismo #neurologia #neurosurgery #residencia medica #TUMOR CEREBRAL

[azveille]

Celyad présentera une mise à jour de ses candidats CYAD-01 et CYAD-101 au 21ème congrès ESMO World GI

Celyad, société biopharmaceutique de stade clinique spécialisée dans le développement de thérapies cellulaires CAR-T, a annoncé que les données cliniques des études de phase 1 SHRINK et alloSHRINK, évaluant la sécurité des candidats CAR-T NKG2D autologues et allogéniques, CYAD-01 et CYAD-101 seront présentées au 21ème congrès mondial sur le cancer gastro- intestinal (WCGIC) de l’ESMO (European Society for Medical Oncology) qui se tiendra à Barcelone, en Espagne, du 3 au 6 juillet 2019. « Nous sommes ravis d’avoir l’opportunité de présenter lors du prochain WCGIC une mise à jour des données cliniques de nos candidats CAR-T NKG2D autologues et allogéniques dans le cadre du traitement du cancer colorectal métastatique réfractaire » a déclaré Frédéric Lehmann, Vice President Clinical Development and Medical Affairs chez Celyad. « Nous continuons à nous appuyer sur notre expérience clinique dans le traitement des tumeurs solides avec ces nouvelles immunothérapies. La présentation orale au WCGIC représente une étape importante qui nous permet de souligner les données préliminaires du premier essai de l’industrie portant sur un candidat CAR-T « prêt à l’emploi » dans le traitement des tumeurs solides. De plus, la similarité des designs d’études SHRINK et alloSHRINK ainsi que les constructions similaires des CARs donne un aperçu des approches autologues et allogéniques dans une indication avancée de tumeur solide. » Détails de la présentation: Abstract #631: Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer Session: Short Oral Presentation

[cancersfakianakis1]

Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Abstract

Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next generation sequencing in the context of clinical practice. Our aim is to rank the level of evidence of individual recurrent genomic alterations observed in breast cancer based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in order to help the clinicians to prioritize treatment. Analyses of databases suggested that there are around 40 recurrent driver alterations in breast cancer. ERBB2 amplification, germline BRCA1/2 mutations, PIK3CA mutations were classified tier of evidence IA based on large randomized trials showing antitumor activity of targeted therapies in patients presenting the alterations. NTRK fusions and MSI were ranked IC. ESR1 mutations and PTEN loss were ranked tier IIA, and ERBB2 mutations and AKT1 mutations tier IIB. Somatic BRCA 1/2 mutations, MDM2 amplifications and ERBB 3 mutations were ranked tier III. Seventeen genes were ranked tier IV based on preclinical evidence. Finally, FGFR1 and CCND1 were ranked tier X alterations because previous studies have shown lack of actionability. http://bit.ly/2Se4Tc0

#Oncology-Sfakianakis